NCT05895773View on ClinicalTrials.gov

Oro-nasal Decontamination to Prevent Ventilator-associated Pneumonia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

June 24, 2023

Primary Completion Date

November 24, 2023

Study Completion Date

November 24, 2023

Conditions
Ventilator Associated Pneumonia
Interventions
DRUG

Povidone-Iodine

Povidone Iodine 0.5% plus glycyrrhizin acid 2.5 mg/ml as a nasal and an oropharyngeal spray (mint flavored) will be applied 4 times per day.

DRUG

Saline spray

Normal saline 0.9% as a nasal and oropharyngeal spray (Mint flavored) will be applied 4 times per day.

Trial Locations (1)

Unknown

Menoufia University hospitals, Shibīn al Kawm

All Listed Sponsors
lead

Menoufia University

OTHER

NCT05895773 - Oro-nasal Decontamination to Prevent Ventilator-associated Pneumonia | Biotech Hunter | Biotech Hunter